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ABSTRACT 
Diabetic Nephropathy (DN) is the foremost reason of End Stage Renal Disease (ESRD) and a major cause of premature deaths amongst people with 
diabetes. It is one of the most common complications of diabetes mellitus (DM) and has majorly influenced patients’ morbidity and mortality. About 
50% of patients suffering from DM for more than 20 years develop this complication. The present review focuses on the global scenario of diabetic 
nephropathy and different molecular mechanisms involved in its pathogenesis i. e. increased formation of advanced glycation end products (AGEs), 
enhanced glucose flux into polyol and hexosamine pathways, activation of protein kinase C (PKC) and other proinflammatory transcription factors. 
This review also highlights the precautionary measures to be taken by people with diabetes along with the therapeutic interventions involving 
angiotensin converting enzyme (ACE) inhibitors, renin inhibitors, angiotensin receptor antagonists, aldosterone antagonists, protein kinase C 
inhibitors, mechanistic target of rapamycin (m-TOR) inhibitors, agents inhibiting plasminogen activator inhibitor-1 (PAI-1), advanced glycation end 
products inhibitors, anti-inflammatory agents and antioxidant agents.  
Keywords: Diabetes Mellitus, Diabetic Nephropathy, End Stage Renal Disease, Advanced Glycation End Products, Protein Kinase C. 
 
INTRODUCTION 
Diabetes mellitus (DM) is a chronic metabolic disorder manifested in 
the form of hyperglycemia as a consequence of defect in insulin 
secretion and/or insulin action along with an imbalance in the 
metabolism of carbohydrates, fats and proteins. The incidence of DM 
has reached epidemic proportions predominantly because of 
changes in lifestyle and increase in the prevalence of obesity, cystic 
fibrosis and mitochondrial defects [1,2]. On a global scale, it is a 
major public health concern as the number of people suffering due 
to diabetes has grown enormously. Recent statistics conducted in 
2011 have stated the prevalence of 366 million people with diabetes 
worldwide, which is estimated to reach 552 million by 2030 [3]. The 
World Health Organization has envisaged a burgeoning rise in 
diabetes especially in countries like India, China and United States 
that are predicted to house the largest number of people with 
diabetes by 2025[4]. Diabetes Mellitus is categorized into two main 
types: Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus. Type 1 
DM, formerly classified as insulin dependent diabetes mellitus 
(IDDM) or juvenile onset diabetes mellitus, is primarily caused by 
autoimmune pancreatic β- cell destruction.  
It is characterized by an absolute deficiency of insulin and subjects 
with type 1 diabetes mellitus are prone to ketoacidosis. Type 2 DM, 
which results from defects in insulin secretion or due to insulin 
resistance, is a frequent form and accounts for more than 90% 
people suffering with diabetes [5-7]. Hyperglycemia is an 
established risk factor for the advancement of diabetes related 
macrovascular and microvascular complications that have a serious 
impact on a patient’s quality of life [8,9]. 
Both type 1 and 2 DM progress to major health complications like 
heart disease, stroke, kidney disease, retinopathy, amputation and 
neuropathy which are the primary reasons for increasing mortality 
and morbidity rates [10].  
Diabetic nephropathy 
Diabetic Nephropathy (DN) is the principal reason of End-Stage 
Renal Disease (ESRD) and a major cause of premature deaths 
amongst patients with diabetes. This mortality is attributed to the 
occurrence of cardiovascular diseases which lead to a 15 fold 
increased risk in DN patients [11]. Prolonged hyperglycemia and 
poor blood pressure control are well known threats for the genesis 
and manifestation of DN [12]. DN is one of the most common 
complications of diabetes mellitus and has profound impact on 
delivery of healthcare. More than one-third of patients with type 
1diabetes and a persistently increasing proportion of patients with 
type 2 diabetes develop renal complications. Approximately one-
third of all the cases of ESRD are due to DN [13]. 
DN is predicted by persistent albuminuria (albumin excretion rate › 
300 mg/24 hrs), diminished glomerular filtration rate and an 
elevated arterial blood pressure. Incipient DN is reflected by a small 
increase in urinary albumin excretion known as microalbuminuria 
(urinary albumin excretion rate (UAER): 20-200 mg/24 hrs) while 
overt DN is distinguished by the presence of macroalbuminuria or 
proteinuria (UAER › 200mg/24 hrs) [12]. DN is classified into 
several distinct phases. Early changes include glomerular 
hyperfiltration and hyperperfusion followed by a silent phase which 
is associated with subtle morphological changes such as thickening 
of the glomerular basement membrane, glomerular hypertrophy, 
mesangial expansion and a modest expansion of the tubulointerstitium. 
It is then followed by microalbuminuria. Post microalbuminuria stage, 
development of proteinuria with established hypertension defines the 
onset of overt nephropathy or macroproteinuria. This finally leads to 
end stage renal failure [14,15]. 
Global scenario of diabetic nephropathy 
Analogous to the rising incidence in diabetes, a remarkable increase 
in the occurrence of DN has been noted along with an increasing 
number of patients requiring renal replacement therapy [16]. About 
50% of patients suffering from DM for more than 20 years have been 
found to develop this complication. Although one third of people 
with type 1 diabetes develop DN, the number of type 2 diabetes 
patients requiring renal transplantation equals or exceeds that of 
type 1 owing to the escalating population of type 2 diabetes patients 
and genetic susceptibility along with hyperglycemia controlling the 
development of DN in people with type 1 diabetes.  
The prevalence of DN is sharply increasing in the developing 
countries with the Asia –Pacific regions being the most severely 
affected ones. The risk of nephropathy in the case of type 2 diabetes 
differs with ethnicity ranging from 25% of individuals from 
European origin to about 50% in other ethnic groups such as Afro-
Caribbean, Asian Indians, and Japanese. A strong familial clustering 
of diabetic nephropathy has been noted among people with type 2 
diabetes in India [11]. 
Diabetes is the single most rising cause of end stage renal failure in 
Europe, particularly in Germany wherein the proportion of patients 
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admitted for renal replacement therapy has exceeded the figure 
reported from the United States [11-17]. 
Diabetic nephropathy in Type 1 and Type 2 Diabetes mellitus 
patients 
As hyperglycemia is the main cause in the development of DN, the 
basic pathophysiological mechanisms giving rise to DN are similar in 
both type 1 and type 2 DM. However, in type 2 diabetes, other 
factors of metabolic syndrome may additionally harm the kidneys 
through uricaemia and obesity, independent of hyperglycemia [18].  
In type 1 diabetes, microalbuminuria appears within 5 to 15 years 
after the onset of diabetes, followed by proteinuria which develops 
in the next 10 years in the absence of medical intervention. The rate 
of development of microalbuminuria and proteinuria in people with 
type 2 diabetes is comparable with that found in type 1 diabetes 
patients [19]. 
In both type 1 and type 2 diabetes, generalized endothelial 
dysfunction is associated with microalbuminuria. Microalbuminuria 
predicts the development of cardiovascular disorders especially in 
type 2 diabetes. 
The clinical manifestations of DN are proteinuria, decreased 
glomerular filtration rate and high blood pressure. Both type 1 and 
type 2 diabetes are characterized by the same manifestations, but 
they differ only in the renal lesions underlying renal dysfunction. 
The lesions in type 2 are more varied with nonspecific and ischemic 
lesions being more uncontrolled. In type 1 diabetes, tubular, 
interstitial and arteriolar lesions are present and the most 
significant structural changes occur in the glomerulus. Despite the 
presence of proteinuria, a number of people with type 2 diabetes 
have been found to have a normal glomerular structure with or 
without tubule-interstitial or arteriolar abnormalities [20,21]. 
Molecular mechanisms of diabetic nephropathy 
Various studies have postulated that hyperglycemia leads to the 
induction of oxidative stress, a condition which increases the 
production of reactive oxygen species (ROS) and decreases the 
antioxidant defence mechanisms of the cell. This imbalance results 
in the initiation of four major pathways involved in the pathogenesis 
of DN viz. AGEs, enhanced glucose flux into the polyol and 
hexosamine pathways and activation of PKC. This further triggers 
proinflammatory transcription factor nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-ĸB) resulting in increased 
inflammatory gene expression, increased expression of transforming 
growth factor-β (TGF- β) & activation of renin-angiotensin-
aldosterone system (RAAS). Collectively these factors result in cell 
injury, apoptosis of podocytes and accumulation of extracellular 
matrix proteins in the glomeruli and tubulointerstitium [22]. 
Increased flux of glucose and other sugars through the polyol 
pathway 
One of the possible reasons for the development of diabetic 
peripheral nephropathy is an abnormal functioning of the polyol 
pathway. The principal enzymes involved in this pathway are aldose 
reductase (AR) and sorbitol dehydrogenase (SDH). AR is found in 
various tissues of the body namely nerve, retina, lens, glomerulus 
and blood vessel wall [23,24]. Since glucose uptake in the 
abovementioned tissues occurs through an insulin independent 
mechanism, a rise in the intracellular glucose concentration is 
observed in parallel with an increasing blood glucose level in these 
tissues. The polyol pathway is involved in the reduction of sugars to 
their respective alcohol forms for e. g. glucose is converted to 
sorbitol and galactose to galactitol by the enzyme AR which is the 
rate limiting enzyme [25,26]. In the former mentioned conversion; 
nicotinamide adenine dinucleotide phosphate (NADPH), which acts 
as a cofactor, is converted into NADP. Sorbitol, thus formed, is 
oxidized to fructose by the enzyme SDH with NAD+ getting reduced 
to NADH [27]. Intracellular accumulation of sorbitol results in 
osmotic damage. Also oxidation of sorbitol causes an increase in the 
cytosolic ratio of NADH/NAD+ thereby inhibiting the enzyme 
glyceraldehyde-3-phosphate dehydrogenase (GDPH) and increasing 
the intracellular concentrations of triose phosphate. Elevated levels 
of triose phosphate increase the formation of methylglyoxal (MG), a 
precursor of AGE, and enhance the production of diacylglycerol 
(DAG) via α-glycerol-3-phosphate which further activates PKC 
[25,26,28]. Activation of PKC increases the production of 
arachidonate and prostaglandin E2 (PGE2) both of which inhibit 
Na+/K+
NADPH is also required as a cofactor to regenerate reduced 
glutathione (GSH), an important scavenger of ROS [30,31]. 
Consumption of NADPH in the reduction of glucose to sorbitol 
results in the decrease of GSH thus exacerbating intracellular 
oxidative stress [29]. Hyperglycemia also inhibits glucose-6-
phosphate dehydrogenase which is one of the major enzymes 
involved in the regeneration of NADPH. 
 ATPase. Thus leading to abnormal blood flow contractility 
and endothelial dysfunction [29].  
 
 
Fig. 1: It shows increased flux of glucose through the polyol 
pathway [25-27,30,31] 
 
Increased intracellular formation of Advanced Glycation End 
Products (AGEs) 
Nonenzymatic reaction between reducing sugars and amino groups 
of proteins, lipids and nucleic acids, also known as Malliard reaction, 
leads to the formation of Schiff’s bases and Amadori products; thus 
finally leading to the production of AGEs [32,33]. The initial stage of 
the reaction leads to the formation of reversible glycosylated 
proteins termed as Schiff’s bases. This stage is rapid and glucose 
dependent. It is followed by a much slower reaction ranging over a 
period of days resulting in the formation of the more stable Amadori 
products. These Amadori products undergo further irreversible 
rearrangement, oxidation and reduction reactions and form several 
advanced glycation end products such as pentosidine, 
N(carboxymethyl)lysine (CML), crossline and pyrolline [34-36]. 
Since these processes occur over a period of weeks, they affect long 
lived proteins e. g. glycated hemoglobin (HbA1c).  
AGEs are produced intracellularly from auto-oxidation of glucose to 
glyoxal, decomposition of amadori products to 3-deoxyglucosone (3-
DG) or fragmentation of glyceraldehyde-3-phosphate to yield MG. All 
these reactive intracellular dicarbonyls react with the amino groups 
of intracellular and extracellular proteins to form AGEs [34-36]. 
Structural components of tissue matrix such as basement 
membranes are important targets of AGEs. Angiotensin II (ANG II) 
triggers the AGEs process. CML and pentosidine accumulate in the 
expanded mesangial area and in the thickened glomerular capillary 
wall in the early phase of diabetic nephropathy [18]. AGEs are also 
formed through alternative glycolytic pathways along with 
dicarbonyl compounds which include MG, glyoxal and 3-DG [37]. 
The diagrammatic representation of same is in the figure 2. 
AGEs exert their biological effects through receptor- as well as non-
receptor mediated mechanisms. Their receptor mediated effects are 
brought about by receptor for advanced glycation end products 
(RAGE), which is a signal transduction receptor belonging to the 
immunoglobulin family and expressed on macrophages, renal 
mesangial cells, endothelial cells and podocytes. Binding of AGEs to 
RAGE leads to a cascade of events which includes increased cytosolic 
reactive oxygen species formation, stimulation of intracellular 
molecules such as PKC and NF-ĸB and activation as well as 
expression of a number of growth factors and cytokines such as TGF-
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β and vascular endothelial growth factor (VEGF) which are involved 
in the pathogenesis of DN [38].  Certain invitro studies have proved 
the enhanced permeability of the glomerular basement membrane 
to albumin as a result of AGE formation on the intact glomerular 
basement membrane; thus resembling the abnormal permeability in 
diabetic nephropathy. Binding of AGE to its receptor on glomerular 
mesangial cells stimulates the secretion of platelet-derived growth 
factor (PDGF) which further mediates mesangial cells to produce 
type IV collagen, laminin and heparin sulphate proteoglycan. 
 
 
Fig. 2: It shows formation of advanced glycation end products 
(AGEs) by three different mechanisms [32-36] 
 
Activation of protein kinase C 
Protein kinase C, existing in several isoforms [39], phosphorylates 
many target proteins. Its activity is dependent on Ca2+ ions & 
phosphatidylserine and is greatly enhanced by DAG. Raised 
intracellular glucose levels enhance glucose flux through the 
glycolytic pathways which in turn increase the availability of triose 
phosphate; thus enhancing the de novo synthesis of DAG leading to 
excessive activation of PKC [40]. Also the increased cytosolic 
NADH/NAD+
Hyperglycemia increases PKC α-, β- and δ isoforms in the 
glomerulus of diabetic rats. Activation of PKC β-isoform results in 
decreased retinal and renal blood flow as a consequence of 
decreased production of vasodilator nitric oxide (NO) &/or 
increased production of endothelin-1(ET-1), a potent 
vasoconstrictor which further stimulates mitogen-activated protein 
kinase (MAPK) activity in the glomerular mesangial cells. Activation 
of PKC also contributes to the accumulation of microvascular matrix 
protein by inducing the expression of TGF-β1, fibronectin and type 
IV collagen in both cultural mesangial cells and in the glomeruli of 
diabetic rats [42]. 
associated with the polyol pathway and the inhibition 
of GDPH by intracellular ROS generated in mitochondria diverts 
glyceraldehyde-3-phosphate away from the glycolytic route and 
targets it towards the production of dihydroxyacetone phosphate 
and DAG [41]. Interaction between AGEs and their cell surface 
receptors results in enhanced activity of PKC.  
 
 
Fig. 3: It shows activation of protein kinase C and other 
mediators leading to DN [40,41,42] 
 
Overactivity of hexosamine pathway  
The hexosamine pathway plays a key role in causing diabetic 
complications. When glucose is high inside the cell, instead of getting 
metabolized through the glycolytic pathway, the fructose-6- 
phosphate formed from glucose-6-phosphate gets diverted into 
hexosamine pathway in which an enzyme, glutamine: fructose-6-
phosphate amidotransferase converts fructose-6-phosphate to 
glucosamine-6-phosphate and finally to uridine di phosphate N-
acetyl glucosamine. 
The N-acetyl glucosamine increases transcription of genes such as 
TGF-α, TGF-β1, PAI-1, Sp-1 which further incorporate transition in 




Fig. 4: It shows damage to the kidney tissues by hexosamine 
pathway [43] 
 
In addition to these four major pathways, diabetic nephropathy can 
be caused through the intervention of other inflammatory mediators 
like m-TOR, PAI-1 etc. 
Prevention of diabetic nephropathy 
Glycemic control 
Good glycemic control can prevent DN in both type I and type II 
diabetes [44]. According to the Diabetes Control & Complications 
Trial (DCCT), optimal control of blood glucose helps in retarding the 
development of diabetic nephropathy. However mere control of 
blood glucose does not prevent its progression, thus suggesting the 
need of alternative therapeutic strategies. 
In Type 1 diabetes with microalbuminuria, improved blood glucose 
level and intensified insulin treatment has been found to prevent the 
aggravation of glomerulopathy [45,46]. Antihyperglycemics such as 
metformin [47] and sulfonylureas [48] which are renally excreted 
should not be prescribed in case of DN if renal function is 
persistently impaired (creatinine > 120μmol/litre) [49,50]. In such 
cases, sulfonylureas like gliazide can be administered whereas 
gliquidone and glipizide can be administered in case of uremia, a 
condition in which sulfonylureas like gliazide cannot be 
administered [51]. 
Dietary control 
A good control on dietary protein intake, about 0.6-0.7 g/kg body 
weight/day, in patients with diabetes is found to have beneficial 
effects on glomerular filtration rate, creatinine clearance and 
albuminuria [11]. Vegetable protein sources have been proved to 
cause less damage to the kidneys as compared to animal sources 
[52]. Simultaneously, care should be taken to avert any unwanted 
side effects of low protein diet and thus, consultation of a 
nutritionist is advisable.  
Increased levels of cholesterol and triglycerides are observed in type 
1 & type 2 diabetes patients with microalbuminuria. Although the 
effects of hypolipidemics (lipid-lowering therapy) in such cases have 
not been reported, dietary restriction, weight reduction and 
improved metabolic control should be considered in all such 
patients.  
Along with the conventional therapies, other dietary or lifestyle 
changes such as curbing down salt and alcohol intake, weight 
reduction, strict exercise regime etc. should be considered 
imperative. 
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Smoking cessation 
Smoking should be discouraged in individuals with diabetes as it 
leads to oxidative stress, increased blood pressure [53], increased 
TGF- β level and impaired vasodilation, all of which are associated 
with the development and progression of diabetic nephropathy. 
Moreover, studies have shown that nephropathy progression 
increases in the case of smokers and also leads to Immunoglobulin A 
(IgA) nephropathy [54,55]. Thus, the presence of diabetes would 
further build up the possibilities of accelerating the progression of 
DN and worsen the overall prognosis. 
Treatment of diabetic nephropathy 
The therapeutic strategies which are currently employed for 
diabetic nephropathy include angiotensin converting enzyme (ACE) 
inhibitors, angiotensin-II AT1 receptor blockers and antioxidants all 
of which have been efficient in improving the functioning of the 
kidney but are ultimately incompetent in reversing the condition. 
Also, evidences suggest that the drugs belonging to these classes are 
capable only in the early stages of DN but prove to be ineffective in 
treating the late stage symptoms. Novel therapeutic interventions 
targeting the key biomarkers implicated in the pathogenesis of DN 
are being investigated to restrain the development and progression 
of this disease [44]. 
Agents modulating the Renin-Angiotensin-Aldosterone System 
(RAAS) 
Angiotensinogen released by the liver, is converted to angiotensin I 
via plasma renin secreted by the juxtaglomerular cells in the kidney. 
Angiotensin I is further converted to angiotensin II by means of the 
angiotensin converting enzyme (ACE) present in the lungs [56]. 
Angiotensin II is a potent vasoactive peptide which increases blood 
pressure through constriction of blood vessels and stimulates the 
secretion of aldosterone from an adrenal cortex, resulting in the 
reabsorption of sodium and water [57]. It is a cogent growth 
modulator, a proinflammatory peptide which degrades bradykinin, a 
vasodilator. Augmented angiotensin II levels generate hypertrophy 
of mesangial and tubular epithelial cells and increase the expression 
of prosclerotic cytokine TGF-β. All these factors contribute to the 
development of nephropathy [58, 59]. 
Angiotensin-converting enzyme inhibitors (ACEI) viz. benazepril, 
lisinopril and angiotensin II receptor blockers (ARBs) viz. valsartan, 
losartan disrupt the renin-angiotensin system and predominantly 
function as renoprotective agents in both hypertensive and 
normotensive states [60]. ACEI demonstrate a superior protective 
effect in hypertensive type 1 and 2 individuals with diabetes than 
ARBs, irrespective of the phase of albuminuria. The latter proves to 
be effective only in the macroalbuminuria phase in both the types of 
diabetes and also decreases systemic vasoconstriction. A 
combinational therapy proves to be more efficient than individual 
drug in the macroalbuminuria phase e. g. benazepril and valsartan 
act synergistically and have an additive effect in preventing DN [61]. 
Direct renin inhibitors such as aliskiren inhibit the renin-
angiotensin-aldosterone system (RAAS) and reduce the feedback 
effects more completely than ACEIs or ARBs; thus providing a 
superior renoprotection [62]. Angiotensin receptor antagonists like 
Candesartan, Irbesartan, Losartan, Valsartan and aldosterone 
antagonists like spironolactone demonstrate an inhibitory effect on 
the renin-angiotensin-aldosterone system and prohibit the 
progression of diabetic nephropathy. 
Calcium channel blockers are diverse class of vasodilatory 
antihypertensive agents and they have been proved to delay the 
disease progression in DN. For example drugs like nicardipine, 
isradipine, etc. have been experimentally proved to be of immense 
therapeutic value in halting the furtherance of DN [44,13,11,51,60]. 
Agents inhibiting protein kinase C 
Ruboxistaurin, an orally active selective inhibitor of the β-isoform of 
PKC has been found to reduce the actions of VEGF. It has also been 
found to stabilize glomerular hyperfiltration, reduce TGF-β levels 
along with subsequent reduction in proteinuria and also decrease 
osteopontin expression and subsequent macrophage infiltration in 
diabetic rats [62]. 
Agents inhibiting m-TOR (mechanistic target of rapamycin) 
Originally known as mammalian target of rapamycin, m-TOR is a 
serine/threonine kinase which plays a crucial role in mediating cell 
size, mass, proliferation and survival. Over-spurring of the m-TOR 
pathway by excess food consumption may be vital factor underlying 
diabetes. This pathway is highly activated in progressive renal 
disorders including DN and causes renal hypertrophy in the early 
stages of diabetes. 
Rapamycin (sirolimus) is a systemic and potent inhibitor of m-TOR. 
It has been found to markedly ameliorate pathological changes and 
renal dysfunction in diabetic db/db mice which were used as a 
model of ESRD associated with DN. It has also been proved 
significant in the reduction of fat deposits and attenuation of 
hyperinsulinemia.  
Sirolimus decreases the expression and activity of glomerular TGF-β 
and VEGF and ameliorates renal inflammation, glomerular 
hypertrophy, and podocyte loss in rats. 
Pentoxifylline has been reported to prohibit the renal expression of 
proinflammatory cytokines, such as tumor necrosis factor-α (TNF-
α), interleukin-1 (IL-1), and IL-6, leading to a decline in the urinary 
cytokine excretion and a reduction in albuminuria [62,63]. 
Agents inhibiting Advanced Glycation End Products (AGEs) 
The diverse strategies targeting the AGE-RAGE interaction involve 
AGE formation inhibitors (ARBs, R-147176, aminoguanidine, 2-3-
Diaminophenazine, thiamine pyrophosphate, benfotiamine, 
pyridoxamine), AGE cross-link breakers (alagebrium, PTB (N-
phenylthiazolium bromide) and ALT-711), RAGE antagonists (PPAR-
γ antagonists), AGE binder (Kremezin) and hypoxia-inducible factor 
(HIF) activators. Drugs such as losartan, olmesartan and hydralazine 
are well-known antihypertensive agents which inhibit the formation 
of AGEs [35,64,65]. 
Agents inhibiting Plasminogen Activator Inhibitor-1(PAI-1) 
Plasminogen is converted to plasmin, which is involved in 
fibrinolysis, tissue remodeling and cell migration. This conversion is 
promoted by tissue type plasminogen activators and urokinase type 
activators. In diabetes, glycation of plasminogen occurs resulting 
into an impaired activation by plasminogen activators. Also the 
levels of these activators are high in diabetic plasma but are 
rendered biologically inactive due to their complex formation with 
plasminogen activator inhibitors-1 (PAI-1). This results into reduced 
conversion of plasminogen to plasmin leading to accumulation of 
extracellular matrix in the glomerulus, a characteristic feature of 
diabetic nephropathy. Binding of PAI-1 to the plasminogen 
activators regulates TGF-β expression and activates the extracellular 
regulated signal kinase/mitogen-activated protein kinase 
(ERK/MAPK) pathways. Rise in the level of PAI-1 inhibits usual 
fibrin clearance mechanism and encourages thrombosis resulting in 
fibrin accumulation in the basement membrane and interstitial 
tissue. PAI-1 is also involved in the renal fibrogenic process that 
occurs in chronic glomerulonephritis, DN, focal segmental 
glomerulosclerosis and other fibrotic renal diseases. The PAI-1 
synthesis or its activity can be inhibited by specific antibodies, 
peptidic antagonists, antisense oligonucleotides or decoy 
nucleotides. Some novel, orally active, small molecule substances – 
TM-5001, TM-5007, TM-5275 – have been found to enhance 
fibrinolysis by inhibiting PAI-1 activity and the formation of complex 
with tissue plasminogen activator [66-68]. 
Antioxidant agents 
Taurine, acetyl- L- carnitine, alpha lipolic acid, vitamin E, ascorbic 
acid, curcumin etc have shown significant reduction in the 
progression of DN. As oxidative stress is one of the major culprits 
leading to the progression of DN, inhibition of the same by 
antioxidant compounds can provide a holistic approach to treat DN 
along with the other forms of therapy [69].  
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Anti inflammatory agents 
Hyperglycemia activates several inflammatory mediators such as 
TNF-α, TNF-β and NF-ĸB which are expressed in the form of cell 
injury, apoptosis of podocytes and accumulation of extracellular 
matrix proteins in the glomeruli and tubulointerstitium. These 
mediators additionally accompany and aggravate DN. Agents which 
can inhibit these mediators can be useful in the treatment of DN. 
Several anti-inflammatory drugs such as cyclooxygenase-2 
inhibitors like meloxicam etc show beneficiary effect in chronic 
diabetes leading to nephropathy [70].  
Aldose reductase inhibitors 
Tolrestat, epalrestat, ranirestat and fidarestat are well-known aldose 
reductase inhibitors which have been reported in the treatment of 
various diabetic complications. Flavonoids such as quercetin, 
naringin, quercitrin, and myricitrin have been proved to play a 
significant role as aldose reductase inhibitors with reference to their 
effect on rat lenses. These drugs either individually or in 
combination can demonstrate a good therapeutic strategy for 
curbing diabetic nephropathy [71,72]. 
CONCLUSION 
We can conclude that with the increasing prevalence of diabetic 
nephropathy globally, there is a need for early diagnosis and a 
therapeutic strategy which will halt its progression. Because of the 
complexity of this disease due to the simultaneous involvement of 
different pathways, one can conclude that there is a need for novel 
therapeutic interventions which will target the key biomarkers 
implicated in the pathogenesis of DN. In addition to this, a 
combination of the therapeutic interventions will be more beneficial 
in arresting the progression of diabetic nephropathy.  Furthermore, 
slowing down the advancement of DN by maintaining a balanced 
glycemic control, blood pressure, dietary control and supplementary 
changes in the life style along with adequate exercise can provide a 
holistic approach in the prevention and treatment of DN. 
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